WALTHAM, Mass., Oct. 18, 2017 /PRNewswire/ -- Respiratory Motion, Inc., announced today its plans to launch the newest version of its ExSpiron 1Xi™ Minute Ventilation (MV) Monitor at the American Society of Anesthesiologists (ASA) in Boston, October 21-25 following recent FDA 510(k) clearance. This new ExSpiron requires no calibration, which greatly expands its range of use. Physicians, nurses, respiratory therapists, EMT's and first responders can now easily assess and measure a patients breathing in seconds.
Respiratory failure is the third most prevalent cause of death in the US. Opioid-induced respiratory depression is increasingly common, not only in the hospital setting but in the community as well. While the opioid epidemic needs to be addressed at multiple levels, the ExSpiron now provides caregivers a convenient method to quickly, accurately and non-invasively assess breathing in a variety of settings. Despite the focus on the dangers of recreational use, opioids continue to be important in delivering pain relief during and after surgery and for certain categories of chronic pain. Similar to alcohol, each individual has a specific sensitivity (or tolerance) to opioids. Finding the right dose to manage pain without causing respiratory depression is challenging. In an era where clinicians and hospitals are concerned with both patient safety and patient satisfaction, safe pain control has become critical.
Respiratory Motion's ExSpiron is the first and only non-invasive monitor that can quickly and accurately assess a person's breathing. The ExSpiron measures Minute Ventilation (MV), Tidal Volume and Respiratory Rate. MV is the fundamental unit of breathing -- the amount of air that moves into and out of the lungs every minute. ExSpiron MV measurements have been shown to be superior to indirect measurements of breathing in numerous peer reviewed studies. These indirect measures are slow to respond when breathing drops to a dangerous level, whereas the ExSpiron responds first and most reliably to changes in breathing. Addressing early changes in respiratory status can prevent further deterioration leading to respiratory failure or arrest.
The new ExSpiron can be used easily and effectively in all areas of the hospital, as well as in the field, providing immediate, quantitative measurements of breathing (MV) when and where they are most needed. With rapid delivery of previously unavailable information about a patient's breathing, the new ExSpiron can be lifesaving.
The newest ExSpiron Minute Ventilation Monitor will be displayed at the ASA Conference, October 21st – 23rd, 2017, at the Boston Convention Center, Exhibit #3623. The broad utility of the newest ExSpiron will be supported by five presentations over the course of the 5 day conference:
- Minute Ventilation Prior to Opioid Dose as a Predictor of Opioid Induced Respiratory Depression in the PACU; Mayo Clinic; October 24, 9:10AM
- Minute Ventilation at PACU Discharge as Predictor for Post-Operative Respiratory Depression on the General Hospital Floor; Cleveland Clinic Foundation; October 24, 9:25AM
- Respiratory Volume Monitoring Postoperatively Can Identify Patients at Risk for Ventilatory Depression Following PACU Discharge; Tufts University Medical Center; October 22, 11:00AM
- Evaluation of a Non-Invasive Respiratory Volume Monitor Without Patient Specific Calibration; University of Texas at Houston; October 25, 10:00 – 11:30AM
- Comparison of Respiratory Volume Monitoring Versus Capnography During Intravenous Propofol-Based Anesthesia; Brigham and Women's Hospital, Harvard Medical School; October 22, 10:00 – 11:30AM
About Respiratory Motion, Inc.
Respiratory Motion, Inc. is the global leader in innovative Minute Ventilation Monitoring, useful across a wide variety of patient populations and environments. Our mission is to improve the quality and experience of care and reduce costs by providing continuous, accurate, real-time, non-invasive respiratory monitoring wherever care is delivered. www.respiratorymotion.com
SOURCE Respiratory Motion, Inc.